Employees: 82
Size Dong-A Socio (000640.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $447M, the 377th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩88,800 on 18 Nov 2026.
Performance Over six months the shares fell 8.2%, against -21.3% for the median peer and -37.2% for the South Korea market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue grew 11.5% over the last twelve months (peer median +4.9%); the operating margin is 7.0% (peer median 4.3%).
Valuation It trades at 7.3× forward earnings against a peer median of 23.1× (cheapest of 6).
Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -19 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.4 points below its cost of capital (5.0% WACC).
Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩1.57T | ₩1.43T | ₩1.33T | ₩1.13T | ₩1.01T |
| Revenue growth | — | +7% | +18% | +12% | — |
| Gross profit | ₩485B | ₩439B | ₩396B | ₩364B | ₩283B |
| EBITDA | ₩202B | ₩193B | ₩171B | ₩151B | ₩109B |
| Net income | ₩69.6B | ₩90.9B | ₩58.0B | ₩58.0B | ₩11.2B |
| Free cash flow | ₩99.8B | ₩154B | ₩12.2B | -₩3.54B | ₩9.12B |
| Capital expenditure | ₩73.9B | ₩58.6B | ₩71.9B | ₩153B | ₩78.6B |
| Total debt | ₩699B | ₩663B | ₩740B | ₩692B | ₩552B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000640.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.3% | -11.1% | 7th highest of 21 |
| 6-month return | -8.2% | -21.3% | 5th highest of 20 |
| Distance from 52-week high | -27.1% | -46.0% | 4th highest of 21 |
| Revenue growth (TTM) | +11.5% | +4.9% | 10th highest of 20 |
| Operating margin | 7.0% | 4.3% | 7th highest of 19 |
| Forward P/E | 7.3× | 23.1× | cheapest of 6 |
| Growth the price implies (Req g, 7 yrs) | -6.6% | 1.4% | 2nd least demanding of 9 |
| Growth delivered (Del g) | +12.8% | +1.1% | 2nd highest of 9 |
| Hurdle (Req g minus delivered) | -19.4 pp | +0.7 pp | least demanding of 9 |
| ROIC minus cost of capital | -0.4 pp | -2.1 pp | 8th highest of 19 |
| EV / EBITDA | 5.5× | 25.9× | cheapest of 4 |
| Net debt / EBITDA | 2.5× | 0.9× | most indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Dong-A Socio 000640.KS | South Korea | $447M | -8% | +11% | 7% | 7.3× | -6.6% | +12.8% |
| Zhejiang Chengyi Pharmaceutical 603811.SS | China | $445M | -21% | +5% | 19% | n/a | 1.3% | +1.3% |
| Pulike Biological Engineering 603566.SS | China | $449M | -21% | -9% | 5% | 23.2× | 4.5% | +3.3% |
| RPG Life Sciences RPGLIFE.NS | India | $443M | +10% | +15% | 17% | n/a | n/a | n/a |
| Gufic Biosciences GUFICBIO.NS | India | $452M | +48% | +17% | 14% | n/a | n/a | n/a |
| Cachet Pharmaceutical 002462.SZ | China | $441M | -25% | -14% | 0% | n/a | -9.9% | -3.4% |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $437M | -16% | -5% | -29% | n/a | n/a | n/a |
| PKU Healthcare 000788.SZ | China | $437M | -12% | -49% | 5% | n/a | -5.6% | -5.6% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $437M | -8% | -17% | -28% | n/a | n/a | n/a |
| Assembly Biosciences ASMB | United States | $458M | -15% | +80% | -32% | n/a | n/a | n/a |
| Kexing Biopharm 688136.SS | China | $433M | -42% | -14% | -12% | 23.1× | n/a | n/a |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $433M | -47% | +35% | 4% | 10.3× | n/a | n/a |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $433M | -48% | +51% | 27% | 12.5× | -0.2% | +14.5% |
| Phathom Pharmaceuticals PHAT | United States | $431M | -55% | +87% | -9% | 39.5× | n/a | n/a |
| BlossomHill Therapeutics BLSM | United States | $464M | n/a | n/a | n/a | n/a | n/a | n/a |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $465M | -28% | +40% | 13% | n/a | 44.1% | +1.0% |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $430M | -30% | +14% | 5% | n/a | 1.4% | -1.3% |
| Kwality Pharmaceuticals KPL.NS | India | $467M | +110% | +48% | 22% | n/a | n/a | n/a |
| Capricor Therapeutics CAPR | United States | $467M | -70% | -100% | n/a | n/a | n/a | n/a |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $427M | +4% | -4% | 3% | n/a | 10.6% | +1.4% |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $468M | -32% | -4% | -11% | n/a | n/a | n/a |